Philogen SpA receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Philogen SpA (PHIL)
Philogen SpA stock price live, this page displays BIT PHIL stock exchange data. View the PHIL premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Philogen SpA real time stock price chart below.
What Is the Philogen SpA Stock Price Today?
The Philogen SpA stock price today is 22.20.
What Is the Stock Symbol for Philogen SpA?
The stock symbol for Philogen SpA is "PHIL."
What Stock Exchange Does Philogen SpA Trade On?
Philogen SpA is listed and trades on the Milan stock exchange.
Is Philogen SpA a Good Stock to Buy?
Determining whether Philogen SpA, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PHIL quote. (ISIN: IT0005373789) Test %CURRENT_YEAR% | %DIVIDEND_YIELD% | %UPSIDE_OR_DOWNSIDE%
What Is the Philogen SpA Stock Price Today?
The Philogen SpA stock price today is 22.20.
What Is the Stock Symbol for Philogen SpA?
The stock symbol for Philogen SpA is "PHIL."
What Stock Exchange Does Philogen SpA Trade On?
Philogen SpA is listed and trades on the Milan stock exchange.
Is Philogen SpA a Good Stock to Buy?
Determining whether Philogen SpA, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PHIL quote. (ISIN: IT0005373789) Test %CURRENT_YEAR% | %DIVIDEND_YIELD% | %UPSIDE_OR_DOWNSIDE%
22.20
+0.30(+1.37%)
Closed·
Fair Value
An estimate of a Philogen SpA's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
21.80
22.45
52 wk Range
19.56
27.80
PHIL is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Philogen SpA's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
21.8022.45
52 wk Range
19.5627.80
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PHIL Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Philogen SpA's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
27.67
Upside
+24.62%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Impressive gross profit margins
- Philogen SpA receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Philogen SpA receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Philogen SpA receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Philogen SpA receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Philogen SpA receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
2 Buy
1 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 27.67
(+24.62% Upside)
Philogen SpA Earnings Call Summary for H2/2025
- Philogen reported EUR 230M net profit for 2025 with EUR 380M cash reserves; approved EUR 0.70 per share dividend and 35% share buyback authorization.
- Product pipeline advanced with Nidlegy and Fibromun showing clinical progress; OncoACP3 partnership with Bristol Myers Squibb/RayzeBio to drive revenue.
- Company maintains diversified revenue from milestones, service activities, and partnerships; expects modest spending increase to EUR 4-5M monthly in 2026.
- Management emphasizes pragmatic approach focusing on financially viable trials with positive outcome expectations while maintaining strong cash position.
Last Updated: 30/03/2026, 16:38
Read Full TranscriptEarnings
Latest Release
Apr 09, 2026
EPS / Forecast
6.04 / --
Revenue / Forecast
311.2M / --
Compare PHIL to Peers and Sector
Metrics to compare | PHIL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPHILPeersSector | |
|---|---|---|---|---|
P/E Ratio | 3.8x | −0.2x | −0.5x | |
PEG Ratio | 0.01 | 0.14 | 0.00 | |
Price/Book | 2.4x | 2.1x | 2.6x | |
Price / LTM Sales | 2.8x | 3.1x | 3.1x | |
Upside (Analyst Target) | 37.0% | 152.3% | 55.1% | |
Fair Value Upside | Unlock | 14.5% | 7.2% | Unlock |
Philogen S.p.A., a biotechnology company, engages in the research and development of drugs for oncology and chronic inflammatory diseases in Italy, Switzerland, the United States, and the European Union. The company develops Nidlegy which is in Phase III clinical trial for the treatment of advanced melanoma and Phase II clinical trial for the treatment of basal cell carcinoma and cutaneous squamous cell carcinoma; Fibromun which is in Phase III clinical trial for the treatment of soft-tissue sarcoma and Phase II clinical trial for the treatment of glioblastoma; Darleukin which is in Phase II clinical trial for the treatment of non-small cell lung cancer; Dekavil which is in Phase II clinical trial for the treatment of chronic inflammatory disorders; and Dodekin which is in Phase I clinical trial for the treatment of various solid tumors. It is also involved in the development of small molecule products, including OncoFAP which is in Phase I clinical trial for the treatment of solid tumors; OncoACP3 which is in Phase I clinical trial for the treatment of prostate cancer; and OncoCAIX which is in Phase 1 trial for the treatment of renal cell carcinoma and other hypoxic tumors. The company was founded in 1996 and is headquartered in Sovicille, Italy.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Philogen SpA (PHIL) Stock Price Today?
The Philogen SpA stock price today is 22.20 EUR.
What Stock Exchange Does Philogen SpA Trade On?
Philogen SpA is listed and trades on the Milan Stock Exchange.
What Is the Stock Symbol for Philogen SpA?
The stock symbol for Philogen SpA is "PHIL."
What Is the Philogen SpA Market Cap?
As of today, Philogen SpA market cap is 882.16M EUR.
What Is Philogen SpA's Earnings Per Share (TTM)?
The Philogen SpA EPS (TTM) is 5.70.
From a Technical Analysis Perspective, Is PHIL a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Philogen SpA Stock Split?
Philogen SpA has split 0 times.
How Many Employees Does Philogen SpA Have?
Philogen SpA has 214 employees.
What is the current trading status of Philogen SpA (PHIL)?
As of May 20, 2026, Philogen SpA (PHIL) is trading at a price of 22.20 EUR, with a previous close of 21.90 EUR. The stock has fluctuated within a day range of 21.80 EUR to 22.45 EUR, while its 52-week range spans from 19.56 EUR to 27.80 EUR.
What Is Philogen SpA (PHIL) Price Target According to Analysts?
The average 12-month price target for Philogen SpA is 27.67 EUR, with a high estimate of 34 EUR and a low estimate of 19 EUR. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +24.62% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.